Should I discontinue Farxiga (dapagliflozin) because I have a rash on my penis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Genital Rash on Dapagliflozin: Management Recommendations

Do not discontinue dapagliflozin immediately for a penile rash; instead, treat the mycotic infection with topical antifungal therapy while continuing the medication, as these infections are typically mild to moderate and respond well to standard treatment without requiring drug discontinuation. 1, 2

Understanding the Risk

  • Genital mycotic infections occur in approximately 4-6% of male patients taking dapagliflozin compared to <1% with placebo, making this a common but manageable side effect 2, 3.

  • The mechanism is directly related to glucosuria (glucose in urine) induced by SGLT2 inhibition, which creates a favorable environment for yeast overgrowth 2.

  • Most infections are mild to moderate in severity and rarely lead to treatment discontinuation (discontinuation rate ≤0.2%) 2, 4.

Initial Management Algorithm

Step 1: Confirm the diagnosis

  • Symptoms of penile yeast infection (balanitis) include redness, itching, swelling of the penis, foul-smelling discharge, rash, and pain in the skin around the penis 1.
  • In uncircumcised men, swelling may develop that makes it difficult to retract the foreskin 1.

Step 2: Initiate topical antifungal treatment

  • Start with over-the-counter topical antifungal medication (e.g., clotrimazole 1% cream applied twice daily for 7-14 days) while continuing dapagliflozin 1, 2.
  • Most infections respond to standard antimicrobial treatment without requiring drug discontinuation 2.

Step 3: Continue dapagliflozin during treatment

  • The cardiovascular and renal protective benefits of dapagliflozin (39% reduction in kidney disease progression, 29% reduction in cardiovascular death or heart failure hospitalization) far outweigh the inconvenience of a treatable genital infection 5, 6.

When to Escalate Care

  • Contact your healthcare provider immediately if symptoms do not improve after 3-5 days of over-the-counter antifungal treatment 1.

  • Seek urgent medical attention if you develop fever, malaise, severe pain, or rapidly spreading erythema in the genital or perineal area, as these may indicate necrotizing fasciitis (Fournier's gangrene)—a rare but serious complication 7, 1.

Prevention Strategies

  • Daily hygiene measures, including gentle cleansing and thorough drying of the genital area, may reduce recurrence risk 6, 1.

  • For uncircumcised men, retract the foreskin daily during bathing and ensure complete drying 1.

When Discontinuation Is Warranted

Discontinue dapagliflozin only if:

  • Recurrent infections occur despite appropriate antifungal treatment and preventive hygiene measures 2.
  • Severe hypersensitivity reaction develops (rash with hives, facial swelling, difficulty breathing) 1, 4.
  • Necrotizing fasciitis is suspected 7, 1.

Critical Context for Your Decision

  • If you are taking dapagliflozin for heart failure or chronic kidney disease (eGFR ≥25 mL/min/1.73 m²), the mortality benefit is substantial—continuing the medication while treating the infection is strongly recommended 5, 6.

  • Hypersensitivity reactions (true allergic rash) are rare with dapagliflozin (4.5% overall, with serious reactions in only 0.2% of patients), and most skin events are infectious rather than allergic 4.

  • The safety profile of dapagliflozin has been confirmed across 21 phase IIb/III trials with over 5,900 patients, showing that genital infections, while more common than placebo, are clinically manageable 4, 2.

References

Research

Dapagliflozin efficacy and safety: a perspective review.

Therapeutic advances in drug safety, 2014

Research

Dapagliflozin in Patients with Chronic Kidney Disease.

The New England journal of medicine, 2020

Guideline

Dapagliflozin Dosing and Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.